The Heart Outcomes Prevention Evaluation (HOPE) study of diabetic patients investigated the role of the ACE inhibitor ramipril in diabetic patients with a cardiovascular risk factor.
3577 patients with diabetes were recruited as part of the HOPE study.
The analysis of the diabetic subgroup of the main trial was planned in advance.
Patients were recruited if they:
The primary outcome was the combination of:
Patients were randomised in a two-by-two factorial manner to:
There were significant benefits for the following end-points in those patients randomised to ramipril:
Reference:
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page